DCM
CORT icon

Davis Capital Management’s Corcept Therapeutics CORT Stock Holding History

Davis Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435 Buy
+5
New +$302 ﹤0.01% 639

Other funds holding CORT

BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Davis Capital Management's CORT Position: Q2 2026 in Review

Davis Capital Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 5 shares worth $435. The stake represents ﹤0.01% of the portfolio and ranks #639 among its holdings.

76 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Davis Capital Management held 5 shares of Corcept Therapeutics worth $435 as of Q2 2026.
  • Corcept Therapeutics was a new Davis Capital Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #639 holding.
  • 76 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.